Evotec and MaRS launched Fibrocor Therapeutics, a company dedicated to developing novel therapeutics for fibrosis.
Evotec and MaRS Innovation launched Fibrocor Therapeutics, a Toronto-based company focused on developing therapeutics targeting fibrotic diseases, on Jan. 17, 2017. The company was launched with approximately $2.1 million in financing, including cash from MaRS Innovation. Evotec will provide all drug discovery activities and will receive an equity stake in Fibrocor.
Fibrocor’s academic and clinical team includes Richard Gilbert MD, PhD, Canada research chair in Diabetic Complications and head of Endocrinology at St. Michael's Hospital and scientist with the hospital's Keenan Research Centre for Biomedical Science, Darren Yuen, MD, PhD, nephrologist with St. Michael's and scientist with the Keenan Research Centre for Biomedical Science, and Jeff Wrana, PhD, senior investigator at Lunenfeld-Tanenbaum Research Institute, Sinai Health System.
The company's core focus will be to develop novel therapeutics that have the potential to prevent, slow, and ultimately reverse the course of fibrosis. Fibrocor has identified a lead program and will partner with Evotec to develop novel molecules with the anticipation of nominating a lead candidate in 2018. Fibrocor will also collaborate with its academic co-founders to expand access to tissue samples to include several relevant tissues, such as lung, liver, kidney, colon, and skin.
Source: Evotec
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.